Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden.
Dobilas A, Jansåker F, Li X, Sundquist K, Borgfeldt C.
BMC Cancer. 2023 Oct 9;23(1):951. doi: 10.1186/s12885-023-11453-6.
Clinical Implication of Borderline CT-Morphological Metastatic Spread in Bladder Cancer: What You See Is Not Always What You Got.
Weinhold P, Jokisch F, Schulz GB, Buchner A, Kazmierczak PM, Kretschmer A, Schlenker B, Karl A, Stief CG, Grimm T.
Urol Int. 2022;106(8):806-815. doi: 10.1159/000521857. Epub 2022 Feb 3.
Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies.
Xu X, Wu J, Mao Y, Zhu Y, Hu Z, Xu X, Lin Y, Chen H, Zheng X, Qin J, Xie L.
PLoS One. 2013;8(3):e58079. doi: 10.1371/journal.pone.0058079. Epub 2013 Mar 5.
M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer.
Aljabery F, Olsson H, Gimm O, Jahnson S, Shabo I.
Urol Oncol. 2018 Apr;36(4):159.e19-159.e26. doi: 10.1016/j.urolonc.2017.11.020. Epub 2017 Dec 26.
Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes.
Kim DK, Kim JW, Ro JY, Lee HS, Park JY, Ahn HK, Lee JY, Cho KS.
J Urol. 2020 Aug;204(2):215-223. doi: 10.1097/JU.0000000000000794. Epub 2020 Jan 31.
Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features.
Oliver-Krasinski JM, Bidot S, Ingram JW, O'Toole KM, McKiernan JM, Tinsley M, Harik LR.
Arch Pathol Lab Med. 2024 Feb 1;148(2):223-229. doi: 10.5858/arpa.2022-0268-OA.
Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary Urothelial Carcinoma after BCG Immunotherapy.
Drachneris J, Morkunas M, Fabijonavicius M, Cekauskas A, Jankevicius F, Laurinavicius A.
Int J Mol Sci. 2024 Apr 27;25(9):4776. doi: 10.3390/ijms25094776.
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients.
You S, Kim M, Widen S, Yu A, Galvan GC, Choi-Kuaea Y, Eyzaguirre EJ, Dyrskjøt L, McConkey DJ, Choi W, Theodorescu D, Chan KS, Shan Y, Tyler DS, De Hoedt AM, Freedland SJ, Williams SB.
Urol Oncol. 2022 Sep;40(9):410.e19-410.e27. doi: 10.1016/j.urolonc.2022.04.013. Epub 2022 May 23.
The Prognostic Impact of Tumor Location in pT3N0M0 Upper Urinary Tract Urothelial Carcinoma: A Retrospective Cohort Study.
Chen TS, Chen YT, Wang HJ, Chiang PH, Yang WC, Lee WC, Chuang YC, Cheng YT, Kang CH, Lee WC, Chen CH, Shen YC, Liu YY, Liu HY, Chang YL, Su YL, Huang CC, Luo HL.
Front Oncol. 2022 Mar 15;12:850874. doi: 10.3389/fonc.2022.850874. eCollection 2022.
Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression.
Jóźwicki W, Brożyna AA, Siekiera J.
Int J Mol Sci. 2014 Sep 11;15(9):16069-82. doi: 10.3390/ijms150916069.
